ImmunityBio Inc’s BLA for N-803 Progresses with FDA Submission, Stock Surges
Clinical-stage immunotherapy company, ImmunityBio, announced on Monday the successful resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for